Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pulmatrix, Inc.

NASDAQ: PULM · Life Sciences · 2 alerts · CIK 1574235

Share price
$1.33Close, Nov 16
Market cap
$4.86M
Shares outstanding
3.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pulmatrix, Inc. filings on SEC EDGAR ↗

9:30 AM ET 8-K
M&A Deal

Pulmatrix M&A Deal with Eos SENOLYTIX, Inc.

Pulmatrix provided a status update on its pending merger with Eos SENOLYTIX, noting that the SEC has declared its Form S-4 registration statement effective and stockholders have approved the deal. The company expects the merger to close by the end of 2026, subject to Nasdaq listing approval and a planned reverse stock split.

Counterparty
Eos SENOLYTIX, Inc.

“Our focus in the third quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel™ platform. To that end, we have obtained SEC effectiveness on our registration statement on Form S-4 in relation to the merger as well as approval from our stockholders on the proposed merger. We anticipate closing the proposed merger by the end of the year.”

Peter Ludlum, Interim Chief Executive Officer of Pulmatrix
9:00 AM ET 8-K
M&A Deal

Pulmatrix M&A Deal with Eos SENOLYTIX, Inc.

Pulmatrix stockholders approved several key proposals related to its pending merger with Eos SENOLYTIX, Inc., including the issuance of common stock representing more than 20% of the company and a change of control. Stockholders also approved a reverse stock split at a ratio between 1-for-2 and 1-for-10 and an increase in authorized shares to facilitate the transaction. The merger will result in Eos becoming a wholly owned subsidiary of Pulmatrix, forming a combined company.

Counterparty
Eos SENOLYTIX, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.